Novo Nordisk Shares Plunge After Cardiovascular Drug Fails Late-Stage Trial

Novo Nordisk (NYSE: NVO) shares plunged as much as 10% on Friday after the company announced its experimental drug, ziltivekimab, failed to meet its primary goal in a late-stage clinical trial, dealing a significant blow to its efforts to diversify beyond its core metabolic franchise.

Key Trial Fails to Show Benefit

The Danish pharmaceutical giant reported that its Phase 3 ZEUS trial did not show a statistically significant reduction in major adverse cardiovascular events (MACE) compared to a placebo. The study evaluated the drug in over 6,300 patients with established atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and systemic inflammation.

The trial posted a hazard ratio of 0.99, indicating no clinical benefit for patients taking ziltivekimab. While the drug successfully achieved its biological targets by inhibiting the IL-6 pathway, this did not translate into a lower risk of cardiovascular death, non-fatal heart attack, or non-fatal stroke. "Despite not achieving the hoped-for MACE benefit, this study provides vital scientific evidence that will help inform our ongoing cardiovascular research," said Martin Holst Lange, Novo Nordisk's Executive Vice President and Chief Scientific Officer, in a statement.

Analyst Downgrades and R&D Concerns

Wall Street analysts reacted swiftly to the news, highlighting the setback for Novo Nordisk's research and development momentum. UBS analyst Matthew Weston described the outcome as "NEGATIVE," noting that the bank had previously modeled $3 billion in peak sales for ziltivekimab, which accounted for 1.7% of the company's Net Present Value (NPV). Weston added that the failure limits Novo's potential to establish cardiovascular therapies as a second major growth pillar.

Ad

Mizuho analyst Jared Holz called the result a "disappointment" that could derail investor sentiment around the company's broader pipeline. Holz noted that the failure could increase pressure on management to pursue more significant mergers and acquisitions to broaden its therapeutic focus beyond obesity-related assets.

Financial and Pipeline Outlook

Novo Nordisk confirmed the trial's outcome will not affect its previously issued 2026 adjusted operating profit outlook. However, the company will recognize a non-cash impairment charge in the third quarter of 2026.

Despite the failure of the ZEUS trial, the company stated that two other cardiovascular trials for ziltivekimab will proceed as planned, with results expected in the first half of 2027. The news also appeared to weigh on other companies in the sector, with shares of industry peers GLUE and BIOA also trading lower in pre-market activity, according to the source report.